<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583424</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-17225</org_study_id>
    <secondary_id>NCI-2018-01039</secondary_id>
    <nct_id>NCT03583424</nct_id>
  </id_info>
  <brief_title>Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of venetoclax when given&#xD;
      together with carmustine, etoposide, cytarabine, and melphalan before stem cell transplant in&#xD;
      treating participants with non-Hodgkin lymphoma that has come back or does not respond to&#xD;
      treatment. Drugs used in chemotherapy, such as venetoclax, carmustine, etoposide, cytarabine,&#xD;
      and melphalan, work in different ways to stop the growth of cancer cells, either by killing&#xD;
      the cells, by stopping them from dividing, or by stopping them from spreading. Giving&#xD;
      chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body&#xD;
      and helps make room in the patient?s bone marrow for new blood-forming cells (stem cells) to&#xD;
      grow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose (MTD) of venetoclax that can be safely combined with&#xD;
      carmustine, etoposide, cytarabine, and melphalan (BEAM) prior to autologous stem cell&#xD;
      transplant which will the recommended phase II dose (RP2D).&#xD;
&#xD;
      II. Determine the safety and efficacy of venetoclax as measured by overall response rate&#xD;
      (ORR) at day 100, 12-month survival and freedom from relapse (FFR-12).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Long term effects (progression-free survival [PFS] and overall survival [OS]) of addition&#xD;
      of venetoclax to BEAM.&#xD;
&#xD;
      II. Correlation of response and survival with expression of BCL-2, BCL-XL, and MCL-1 as&#xD;
      measured by immunohistochemistry (IHC).&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of venetoclax.&#xD;
&#xD;
      Participants receive venetoclax orally (PO) once daily (QD) on days -10 to -1, carmustine&#xD;
      intravenously (IV) on day -6, etoposide IV twice daily (BID) on days -5 to -2, cytarabine IV&#xD;
      BID on days -5 to -2, and melphalan IV on day -1. Participants then undergo hematopoietic&#xD;
      stem cell transplantation on day 0.&#xD;
&#xD;
      After completion of study treatment, participants are followed up for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of venetoclax defined to be the dose cohort below which 3 out of 6 patients experience dose limiting toxicities or the highest dose cohort of 1200 mg, if 2 dose limiting toxicities are not observed at any dose cohort</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>At day 100</time_frame>
    <description>Will be estimated as the proportions of patients who achieve a complete response or partial response divided by the number of evaluable patients. Each will be reported with their associated 95% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of progression</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Estimated using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of freedom from relapse</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Estimated using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Estimated using Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Hematopoietic Cell Transplantation Recipient</condition>
  <condition>Recurrent Diffuse Large B-Cell Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma</condition>
  <condition>Refractory Follicular Lymphoma</condition>
  <condition>Refractory Marginal Zone Lymphoma</condition>
  <condition>Refractory Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Transformed Indolent Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (venetoclax, BEAM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive venetoclax PO QD on days -10 to -1, carmustine IV on day -6, etoposide IV BID on days -5 to -2, cytarabine IV BID on days -5 to -2, and melphalan IV on day -1. Participants then undergo hematopoietic cell transplantation on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (venetoclax, BEAM)</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Becenum</other_name>
    <other_name>Becenun</other_name>
    <other_name>BiCNU</other_name>
    <other_name>Bis(chloroethyl) Nitrosourea</other_name>
    <other_name>Bis-Chloronitrosourea</other_name>
    <other_name>Carmubris</other_name>
    <other_name>Carmustin</other_name>
    <other_name>Carmustinum</other_name>
    <other_name>FDA 0345</other_name>
    <other_name>Gliadel</other_name>
    <other_name>N,N'-Bis(2-chloroethyl)-N-nitrosourea</other_name>
    <other_name>Nitrourean</other_name>
    <other_name>Nitrumon</other_name>
    <other_name>SK 27702</other_name>
    <other_name>SRI 1720</other_name>
    <other_name>WR-139021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (venetoclax, BEAM)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (venetoclax, BEAM)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Cell Transplantation</intervention_name>
    <description>Undergo hematopoietic cell transplantation</description>
    <arm_group_label>Treatment (venetoclax, BEAM)</arm_group_label>
    <other_name>HCT</other_name>
    <other_name>Hematopoietic Stem Cell Transplantation</other_name>
    <other_name>HSCT</other_name>
    <other_name>stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (venetoclax, BEAM)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine nitrogen mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (venetoclax, BEAM)</arm_group_label>
    <other_name>ABT-0199</other_name>
    <other_name>ABT-199</other_name>
    <other_name>ABT199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>RG7601</other_name>
    <other_name>Venclexta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have histologically confirmed diagnosis of non-Hodgkin?s lymphoma that&#xD;
             has relapsed, or is refractory, after upfront induction therapy. Excluded histologies&#xD;
             are T-cell lymphomas, post-transplant lymphoproliferative disorder, Burkitt lymphoma,&#xD;
             lymphoblastic lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma. All&#xD;
             other histologies are eligible that include but not limited to: diffuse-large B-cell&#xD;
             lymphoma, follicular lymphoma (grades I, II, and III), marginal zone lymphoma,&#xD;
             transformed indolent lymphoma, grey zone lymphoma, and undifferentiated B-cell&#xD;
             lymphoma. Patients with non-Hodgkin's lymphoma (NHL) who are at high risk of relapse&#xD;
             can be enrolled in sustained partial response (PR) after induction chemotherapy (PR1)&#xD;
&#xD;
          -  Expected survival of more than six months&#xD;
&#xD;
          -  Karnofsky performance status &gt;= 80%&#xD;
&#xD;
          -  Within 1 week prior to initiation of treatment: Aspartate aminotransferase&#xD;
             (AST)/alanine aminotransferase (ALT) &lt; 3 x upper limits of normal (ULN) unless due to&#xD;
             disease&#xD;
&#xD;
          -  Within 1 week prior to initiation of treatment: Total bilirubin &lt; 2 x ULN unless due&#xD;
             to disease&#xD;
&#xD;
          -  Within 1 week prior to initiation of treatment: Calculated glomerular filtration rate&#xD;
             (GFR) 30 ml/min&#xD;
&#xD;
          -  Within 1 week prior to initiation of treatment: Absolute neutrophil count (ANC) &gt; 500&#xD;
             cells/mm^3&#xD;
&#xD;
          -  Within 1 week prior to initiation of treatment: Platelet count &gt; 50 mm^3&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt;= 40%&#xD;
&#xD;
          -  Diffusion capacity of carbon monoxide (DLCO) &gt;= 50% predicted&#xD;
&#xD;
          -  Ability to collect 2 x 10^6/kg CD34+ cells for transplantation&#xD;
&#xD;
          -  Patient must be otherwise eligible for autologous stem cell transplantation (ASCT) per&#xD;
             local institutional guidelines&#xD;
&#xD;
          -  No serious disease, or condition, that, in the opinion of the investigator, would&#xD;
             compromise the patient?s ability to participate in the study&#xD;
&#xD;
          -  Subjects must have the ability to understand and the willingness to sign a written&#xD;
             informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who sustained a complete metabolic response (CMR) by positron emission&#xD;
             tomography (PET)-computed tomography (CT) (Deauville score of =&lt; 3) after salvage&#xD;
             chemotherapy unless lymphoma relapsed less than 12 months from the first day of last&#xD;
             cycle of induction chemotherapy OR patient required more than 2 lines of salvage&#xD;
             chemotherapy to sustain a CMR&#xD;
&#xD;
          -  Subjects receiving any other investigational agents&#xD;
&#xD;
          -  Prior treatment with venetoclax&#xD;
&#xD;
          -  Patients with central nervous system (CNS) involved by lymphoma can be included if CNS&#xD;
             disease is deemed controlled prior to enrollment as determined by the investigator.&#xD;
             Patients with uncontrolled CNS disease will be excluded&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to venetoclax or other agents used in this study&#xD;
&#xD;
          -  Subjects with uncontrolled intercurrent illness including, but not limited to ongoing&#xD;
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             cardiac arrhythmia, or psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements&#xD;
&#xD;
          -  Patients who are human immunodeficiency virus (HIV) positive and receiving combination&#xD;
             antiretroviral therapy will be excluded; because of the potential for pharmacokinetic&#xD;
             interactions with venetoclax&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding. Confirmation that the subject is&#xD;
             not pregnant must be established by a negative serum beta-human chorionic gonadotropin&#xD;
             (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not&#xD;
             required for post-menopausal or surgically sterilized women. Male or female patients,&#xD;
             who are sexually active and of the child bearing age, must be willing to practice&#xD;
             accepted birth control measures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kami Maddocks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Kami Maddocks</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

